Araştırma Makalesi
BibTex RIS Kaynak Göster

VCAM1 (T-1591C and T-833C) and E-selectin S128R polymorphisms are not risk factors for Hashimoto’s thyroiditis

Yıl 2018, , 138 - 142, 30.11.2018
https://doi.org/10.25000/acem.421521

Öz

Aim: The etiopathogenesis of Hashimoto’s thyroiditis (HT)  has not been clearly elucidated although the
role of chronical inflammation and endothelial dysfunction has been
established.   Adhesion molecules such as vascular cell adhesion molecule1
(VCAM1) and E-selectin are secreted from vascular endothelium and promote
accummulation of leukocytes in damaged endothelial areas.  This
study examined the possible association of VCAM1 (T-1591C and T-833C)
and E-selectin S128R single nucleotide polymorphisms
(SNPs) with the occurence of HT for the first time.

Methods: VCAM1 (T-1591C and T-833C), and E-selectin
S128R SNPs in DNA from peripheral blood leukocytes of 189
patients with HT and 247 healthy controls were investigated by real-time PCR
combined with melting curve analysis using fluorescence-labeled hybridization
probes.

Results: We did not find
significant differences in the distributions of studied polymorphisms   between patients with HT and healthy
controls.







Conclusions: The
results of present study suggest that
VCAM1 (T-1591C and T-833C) and
E-selectin S128R SNPs
may not be risk factors for HT. For all that; further
studies with a larger cohort, analyzing other polymorphisms in
VCAM1 and E-selectin genes
are necessary to support our observations.

Kaynakça

  • 1. Klecha AJ, Barriero Arcos ML, Frick L, Genaro AM, Cremaschi G. Immune-endocrine interactions in autoimmune thyroid disease. Neuroimmunomodulation. 2008;15:68-75.
  • 2. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired endothelium-dependent vasodialatation in subclinical hypothyroidism: benefical effects of levothyroxin therapy. J Clin Endocrinol Metab. 2003;88:3731-7.
  • 3. Erden S, Buyukozturk S, Vural P, Degirmencioglu S. Acute-phase reactants in Hashimoto thyroiditis. Int Immunopharmacol. 2008;8:1863- 5.
  • 4. Gonzales-Amaro R, Sanchez-Madrid F. Cell adhesion molecules: selectins and integrins. Crit Rev Immunol. 1999;19:389-429.
  • 5. Marazuela M, Postigo A, Acevedo A, Diaz-Gonzalez F, Sanchez-Madrid F, de Landzuri MO. Adhesion molecules from the LFA-1/ ICAM-1,3 and VLA-4/VCAM-1 pathways on lymphocytes and vascular endothelium in Graves’ disease and Hashimoto’s thyroid gland. Eur J Immunol. 1994;24:2483-90.
  • 6. Marazuela M, Carcia-Lopez MA, Fifueroa-Vega N, de la Fuente H, Alvarado-Sanchez B, Monsivais-Urenda A, et al. Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab. 2006;91:3639-46.
  • 7. Jublanc C, Beaudeux JL, Aubart F, Raphael M, Chadarevian R, Chapman MJ, et al. Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1, are elevated in patients with autoimmune thyroid disorders: relevance to vascular inflammation. Nutr Metab Cardiovasc. 2011;21:817-22.
  • 8. Lu M, Fang P, Zhang Z, He H, Gao S, Hou B, et al. A preliminary clinical application of ICAM-1 RIA in three kinds of thyroid disease. Clin Med J (Engl). 2002;115:1552-5.
  • 9. Pesce G, Fiorino N, Riccio AM, Montagna P, Torre G, Salmaso C, et al. Different intrathyroid expression of intercellular adhesion molecule-1 (ICAM-1) in Hashimoto's thyroiditis and Graves' disease: analysis at mRNA level and association with B7.1 costimulatory molecule. J Endocrinol Invest. 2002; 25:289-95.
  • 10. Chen HY, Cui B, Wang S, Zhao ZF, Sun H, Zhao YJ, et al. L-selectin gene polymorphisms in Graves’ disease. Clin Endocrinol. 2007;67:145-51.
  • 11. Chen H, Cui B, Wang S, Zhao Z, Sun H, Gu X, et al. The common variants of E-selectin gene in Graves’ disease. Genes Immun. 2008;9:182-6.
  • 12. El-Magadmi M, Alansari A, Teh LS, Ordi J, Gül A, Inanç M, et al. Association ofthe A561C E-selectin polymorphism with systemic lupus erythematosus in 2 independent populations. J Rheumatol. 2001;28:2650-2.
  • 13. Podgoreanu MV, White WD, Morris RW, Mathew JP, Stafford-Smith M, Welsby IJ, et al. Inflammatory gene plymorphisms and risk of postoperative myocardial infarction after cardiac surgery. Circulation. 2006;114:I-275-81.
  • 14. Krueger M, Puthoutu B, Heinze J, Foster J, Heinzmann A. Genetic polymorphisms of adhesion molecules in children with severe RSV-associated disease. Int J Immunogenet. 2006;33:233-5.
  • 15. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191-203.
  • 16. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, et al. Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 2000;92:1329-36.
  • 17. Koch AE, Halloran MM, Haskell CJ, Shan MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995;376:517-9.
  • 18. Taylor JG, Tang DC, Savage SA, Leitman SF, Heller SI, Serjeant GR, et al. Variants in the VCAM1 gene and the risk for symptomatic stroke in sickle cell disease. Blood. 2002;100:4303-9.
  • 19. Bielinski SJ, Pankow JS, Li N, Hsu FC, Adar SC, Jenny NS, et al. ICAM1 and VCAM1 polymorphisms, coronary artery calcium, and circulating levels of soluble ICAM-1: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2008;201:339-44.
  • 20. Idelman G, Taylor JG, Tongbai R, Chen RA, Haggerty CM, Bilke S, et al. Functional profiling of uncomon VCAM1 promoter polymorphisms prevalent in African American population. Hum Mutat. 2007;28:824-9.
  • 21. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223-9.
  • 22. Yoshida M, Takano Y, Sasaoka T, Izumi T, Kimura A. E-selectin polymorphism associated with myocardial infarction causes enhanced leukocyte-endothelial interactions under flow conditions. Atheroscler Thromb Vasc Biol. 2003;23:783-8.
  • 23. Abu-Amero KK, Al-Mohanna F, Al-Boudari OM, Mohamed GH, Dzimiri N. The interactive role of type 2 diabetes mellitus and R-selectin S128R mutation on susceptibility to coronary heart disease. BMC Med Genet. 2007;8:35-40.
  • 24. Wenzel K, Ernst M, Rohe K, Baumann G, Speer B, Waldhausl W. DNA polymorphism in adhesion molecule genes – a new factor for early atherosclerosis. Hum Genet. 1996;97:15-20.
  • 25. Mlekusch W, Exner M, Schillinger M, Sabeti S, Mannhalter C, Minar E, et al. E-selectin and restenosis after femoropopliteal angioplasty: prognostic impact of the Ser128Arg genotype and plasma levels. Thromb Haemostasis. 2004;91:171-9.

VCAM1 (T-1591C ve T-833C) ve E-selektin S128R polimorfizmleri Hashimoto tiroiditi için risk faktörleri değildir

Yıl 2018, , 138 - 142, 30.11.2018
https://doi.org/10.25000/acem.421521

Öz

Amaç: Hashimoto tiroiditinin (HT) etyopatogenezi tam
olarak aydınlatılamamış olmakla birlikte kronik inflamasyon ve endotel
disfonksiyonunun önemli olduğu bilinmektedir. Vasküler hücre adezyon molekülü 1
(VCAM1) ve E-selektin gibi adezyon molekülleri endotel tarafından salgılanırlar
ve hasarlı endotel bölgesine lökositlerin migrasyonunu düzenlemektedirler. Bu
çalışmada ilk kez VCAM1 (T-1591C ve T-833C) ve E-selektin S128R tek nükleotid
polimorfizmleri (SNPs) ile HT arasında bir ilişki olup olmadığı
araştırılmıştır.

Metod: HT’li 189 hasta ve 247 sağlıklı kontrol kişinin
periferik kan lökositlerinden izole edilen DNA örneklerinde VCAM1  (T-1591C ve T-833C) ile E-selektin S128R
polimorfizmleri floresan boya-işaretli problar kullanan ve erime eğri analizine
dayanan “real-time” PCR yöntemi ile incelendi.

Bulgular: Çalışmamızda kontrol grubu ve HT hastalarında
araştırılan polimorfizmlerin dağılımlarında anlamlı bir fark bulunmadığı
saptandı.







Sonuç: Bu çalışmanın
bulgularına göre VCAM1 (T-1591C ve T-833C) ve E-selektin S128R polimorfizmleri
HT için bir risk faktörü olmayabileceğini düşündürmektedir. Bununla birlikte,
bulgularımızın desteklenmesi için örnek sayısının arttırılması, ayrıca VCAM1 ve
E-selektin genlerin farklı polimorfik lokuslarının da incelenmesi gerektiği
kanısındayız.

Kaynakça

  • 1. Klecha AJ, Barriero Arcos ML, Frick L, Genaro AM, Cremaschi G. Immune-endocrine interactions in autoimmune thyroid disease. Neuroimmunomodulation. 2008;15:68-75.
  • 2. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired endothelium-dependent vasodialatation in subclinical hypothyroidism: benefical effects of levothyroxin therapy. J Clin Endocrinol Metab. 2003;88:3731-7.
  • 3. Erden S, Buyukozturk S, Vural P, Degirmencioglu S. Acute-phase reactants in Hashimoto thyroiditis. Int Immunopharmacol. 2008;8:1863- 5.
  • 4. Gonzales-Amaro R, Sanchez-Madrid F. Cell adhesion molecules: selectins and integrins. Crit Rev Immunol. 1999;19:389-429.
  • 5. Marazuela M, Postigo A, Acevedo A, Diaz-Gonzalez F, Sanchez-Madrid F, de Landzuri MO. Adhesion molecules from the LFA-1/ ICAM-1,3 and VLA-4/VCAM-1 pathways on lymphocytes and vascular endothelium in Graves’ disease and Hashimoto’s thyroid gland. Eur J Immunol. 1994;24:2483-90.
  • 6. Marazuela M, Carcia-Lopez MA, Fifueroa-Vega N, de la Fuente H, Alvarado-Sanchez B, Monsivais-Urenda A, et al. Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab. 2006;91:3639-46.
  • 7. Jublanc C, Beaudeux JL, Aubart F, Raphael M, Chadarevian R, Chapman MJ, et al. Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1, are elevated in patients with autoimmune thyroid disorders: relevance to vascular inflammation. Nutr Metab Cardiovasc. 2011;21:817-22.
  • 8. Lu M, Fang P, Zhang Z, He H, Gao S, Hou B, et al. A preliminary clinical application of ICAM-1 RIA in three kinds of thyroid disease. Clin Med J (Engl). 2002;115:1552-5.
  • 9. Pesce G, Fiorino N, Riccio AM, Montagna P, Torre G, Salmaso C, et al. Different intrathyroid expression of intercellular adhesion molecule-1 (ICAM-1) in Hashimoto's thyroiditis and Graves' disease: analysis at mRNA level and association with B7.1 costimulatory molecule. J Endocrinol Invest. 2002; 25:289-95.
  • 10. Chen HY, Cui B, Wang S, Zhao ZF, Sun H, Zhao YJ, et al. L-selectin gene polymorphisms in Graves’ disease. Clin Endocrinol. 2007;67:145-51.
  • 11. Chen H, Cui B, Wang S, Zhao Z, Sun H, Gu X, et al. The common variants of E-selectin gene in Graves’ disease. Genes Immun. 2008;9:182-6.
  • 12. El-Magadmi M, Alansari A, Teh LS, Ordi J, Gül A, Inanç M, et al. Association ofthe A561C E-selectin polymorphism with systemic lupus erythematosus in 2 independent populations. J Rheumatol. 2001;28:2650-2.
  • 13. Podgoreanu MV, White WD, Morris RW, Mathew JP, Stafford-Smith M, Welsby IJ, et al. Inflammatory gene plymorphisms and risk of postoperative myocardial infarction after cardiac surgery. Circulation. 2006;114:I-275-81.
  • 14. Krueger M, Puthoutu B, Heinze J, Foster J, Heinzmann A. Genetic polymorphisms of adhesion molecules in children with severe RSV-associated disease. Int J Immunogenet. 2006;33:233-5.
  • 15. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191-203.
  • 16. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, et al. Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 2000;92:1329-36.
  • 17. Koch AE, Halloran MM, Haskell CJ, Shan MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995;376:517-9.
  • 18. Taylor JG, Tang DC, Savage SA, Leitman SF, Heller SI, Serjeant GR, et al. Variants in the VCAM1 gene and the risk for symptomatic stroke in sickle cell disease. Blood. 2002;100:4303-9.
  • 19. Bielinski SJ, Pankow JS, Li N, Hsu FC, Adar SC, Jenny NS, et al. ICAM1 and VCAM1 polymorphisms, coronary artery calcium, and circulating levels of soluble ICAM-1: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2008;201:339-44.
  • 20. Idelman G, Taylor JG, Tongbai R, Chen RA, Haggerty CM, Bilke S, et al. Functional profiling of uncomon VCAM1 promoter polymorphisms prevalent in African American population. Hum Mutat. 2007;28:824-9.
  • 21. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223-9.
  • 22. Yoshida M, Takano Y, Sasaoka T, Izumi T, Kimura A. E-selectin polymorphism associated with myocardial infarction causes enhanced leukocyte-endothelial interactions under flow conditions. Atheroscler Thromb Vasc Biol. 2003;23:783-8.
  • 23. Abu-Amero KK, Al-Mohanna F, Al-Boudari OM, Mohamed GH, Dzimiri N. The interactive role of type 2 diabetes mellitus and R-selectin S128R mutation on susceptibility to coronary heart disease. BMC Med Genet. 2007;8:35-40.
  • 24. Wenzel K, Ernst M, Rohe K, Baumann G, Speer B, Waldhausl W. DNA polymorphism in adhesion molecule genes – a new factor for early atherosclerosis. Hum Genet. 1996;97:15-20.
  • 25. Mlekusch W, Exner M, Schillinger M, Sabeti S, Mannhalter C, Minar E, et al. E-selectin and restenosis after femoropopliteal angioplasty: prognostic impact of the Ser128Arg genotype and plasma levels. Thromb Haemostasis. 2004;91:171-9.
Toplam 25 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm Orjinal Makale
Yazarlar

Sevgin Degirmencioglu

Pervin Vural

Ayşenur Özderya Bu kişi benim

Semra Dogru Abbasoglu Bu kişi benim

Yayımlanma Tarihi 30 Kasım 2018
Yayımlandığı Sayı Yıl 2018

Kaynak Göster

Vancouver Degirmencioglu S, Vural P, Özderya A, Dogru Abbasoglu S. VCAM1 (T-1591C and T-833C) and E-selectin S128R polymorphisms are not risk factors for Hashimoto’s thyroiditis. Arch Clin Exp Med. 2018;3(3):138-42.